Osterweis Capital Management Inc. Makes New Investment in Repligen Corporation $RGEN

Osterweis Capital Management Inc. bought a new stake in Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, Holdings Channel reports. The firm bought 110,995 shares of the biotechnology company’s stock, valued at approximately $15,144,000.

A number of other institutional investors have also modified their holdings of RGEN. United Capital Financial Advisors LLC purchased a new stake in shares of Repligen during the third quarter worth approximately $368,387,000. Opti Capital Management LP purchased a new position in Repligen in the 4th quarter valued at $2,399,209,000. Maverick Capital Ltd. purchased a new position in Repligen in the 1st quarter valued at $178,946,000. Wasatch Advisors LP acquired a new position in Repligen in the 1st quarter valued at $146,513,000. Finally, Price T Rowe Associates Inc. MD increased its stake in Repligen by 31.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Zacks Research upgraded shares of Repligen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Wells Fargo & Company boosted their price target on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Barclays increased their price target on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Finally, HSBC lowered their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Wednesday, June 3rd. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $166.43.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $181.62 on Tuesday. The firm has a market capitalization of $10.25 billion, a P/E ratio of 248.79, a PEG ratio of 3.31 and a beta of 1.03. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The company’s fifty day moving average is $148.17 and its two-hundred day moving average is $131.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter last year, the firm posted $0.26 EPS. The business’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Analysts forecast that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.60% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.